{"id":15320,"date":"2021-02-07T21:00:00","date_gmt":"2021-02-07T18:00:00","guid":{"rendered":"http:\/\/www.saranghanguk.ro\/?p=15320"},"modified":"2021-02-08T14:41:05","modified_gmt":"2021-02-08T11:41:05","slug":"coreea-de-sud-aproba-tratamentul-covid-19-dezvoltat-de-compania-coreeana-celltrion-pentru-uz-conditionat","status":"publish","type":"post","link":"https:\/\/www.saranghanguk.ro\/index.php\/2021\/02\/07\/coreea-de-sud-aproba-tratamentul-covid-19-dezvoltat-de-compania-coreeana-celltrion-pentru-uz-conditionat\/","title":{"rendered":"Coreea de Sud aprob\u0103 TRATAMENTUL COVID-19 dezvoltat de compania coreean\u0103 Celltrion pentru uz condi\u021bionat"},"content":{"rendered":"\n<p id=\"tw-target-text\">Ministerul Siguran\u021bei Alimentelor \u0219i Medicamentelor din Coreea de Sud  a anun\u021bat, de cur\u00e2nd, c\u0103 a aprobat cererea de folosire a tratamentului pentru  COVID-19 al gigantului farmaceutic Celltrion Inc. cu mai multe condi\u021bii, potrivit Yonhap.<\/p>\n\n\n\n<p id=\"tw-target-text\">Autoriza\u021bia condi\u021bionat\u0103 de introducere pe pia\u021b\u0103 a CT-P59, un candidat la tratament anticorp monoclonal anti-COVID-19, marcheaz\u0103 primul tratament COVID-19 din \u021bar\u0103.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" width=\"740\" height=\"493\" src=\"http:\/\/www.saranghanguk.ro\/wp-content\/uploads\/2020\/12\/optimize-3.jpg\" alt=\"\" class=\"wp-image-14273\" srcset=\"https:\/\/www.saranghanguk.ro\/wp-content\/uploads\/2020\/12\/optimize-3.jpg 740w, https:\/\/www.saranghanguk.ro\/wp-content\/uploads\/2020\/12\/optimize-3-300x200.jpg 300w, https:\/\/www.saranghanguk.ro\/wp-content\/uploads\/2020\/12\/optimize-3-90x60.jpg 90w\" sizes=\"(max-width: 740px) 100vw, 740px\" \/><\/figure>\n\n\n\n<p id=\"tw-target-text\">Ministerul Coreean pentru Siguran\u021ba Alimentelor \u0219i Medicamentelor a declarat c\u0103 CT-P59 poate fi administrat pacien\u021bilor cu COVID-19 care prezint\u0103 un risc mai mare, referindu-se la persoanele \u00een v\u00e2rst\u0103 de  peste 60 de ani sau cele  cu afec\u021biuni de s\u0103n\u0103tate precum boli de inim\u0103, diabet, presiune ridicat\u0103 sau boli cronice care afecteaz\u0103 sistemul respirator.<\/p>\n\n\n\n<p id=\"tw-target-text\">Ministerul a oferit autorizarea aceasta cu condi\u021bia ca  reprezentan\u021bii Celltrion s\u0103 prezinte rezultatele studiului clinic global de faz\u0103 3.<\/p>\n\n\n\n<p id=\"tw-target-text\">Vreau s\u0103 v\u0103 aduc aminte c\u0103 luna trecut\u0103, Celltrion a anun\u021bat rezultate din studiul s\u0103u clinic de faza a doua global\u0103, spun\u00e2nd c\u0103 CT-P59 reduce timpul de recuperare \u0219i  m\u0103re\u0219te \u0219ansele  \u00een cazurile de infectare  mai severe.<\/p>\n\n\n\n<p>Celltrion inten\u021bioneaz\u0103 s\u0103 desf\u0103\u0219oare un studiu clinic global, mai exact faza a 3 a, care constituie o  parte esen\u021bial\u0103, \u00een mai mult de 10 \u021b\u0103ri, pentru a ob\u021bine rezultate mai cuprinz\u0103toare privind siguran\u021ba \u0219i eficacitatea  tratamentului CT-P59.<\/p>\n\n\n\n<p>De asemenea, compania pl\u0103nuie\u0219te,  s\u0103 trimit\u0103 o cerere de autorizare a utiliz\u0103rii de urgen\u021b\u0103 a tratamentului la Administra\u021bia SUA pentru Alimente \u0219i Medicamente \u0219i pentru autoriza\u021bie de comercializare condi\u021bionat\u0103 la Agen\u021bia European\u0103 pentru Medicamente (EMA) \u00een urm\u0103toarele luni.<\/p>\n\n\n\n<p>CT-P59 reprezint\u0103 un tratament anticorp monoclonal anti-COVID-19 ce a fost realizat \u00een colaborare cu Ministerul Siguran\u021bei Alimentelor \u0219i Medicamentelor.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ministerul Siguran\u021bei Alimentelor \u0219i Medicamentelor din Coreea de Sud a anun\u021bat, de cur\u00e2nd, c\u0103 a aprobat cererea de folosire a..<\/p>\n","protected":false},"author":8,"featured_media":14273,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[17],"tags":[3439,3441,3569,3571,3438,3570],"_links":{"self":[{"href":"https:\/\/www.saranghanguk.ro\/index.php\/wp-json\/wp\/v2\/posts\/15320"}],"collection":[{"href":"https:\/\/www.saranghanguk.ro\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.saranghanguk.ro\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.saranghanguk.ro\/index.php\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.saranghanguk.ro\/index.php\/wp-json\/wp\/v2\/comments?post=15320"}],"version-history":[{"count":27,"href":"https:\/\/www.saranghanguk.ro\/index.php\/wp-json\/wp\/v2\/posts\/15320\/revisions"}],"predecessor-version":[{"id":15375,"href":"https:\/\/www.saranghanguk.ro\/index.php\/wp-json\/wp\/v2\/posts\/15320\/revisions\/15375"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.saranghanguk.ro\/index.php\/wp-json\/wp\/v2\/media\/14273"}],"wp:attachment":[{"href":"https:\/\/www.saranghanguk.ro\/index.php\/wp-json\/wp\/v2\/media?parent=15320"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.saranghanguk.ro\/index.php\/wp-json\/wp\/v2\/categories?post=15320"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.saranghanguk.ro\/index.php\/wp-json\/wp\/v2\/tags?post=15320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}